Performance of the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and First Steps towards Global Harmonization of COVID-19 Antibody Methods-Reference-Cited by-同舟云学术

Performance of the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and First Steps towards Global Harmonization of COVID-19 Antibody Methods

Published:2021-08-18 Issue:9 Volume:59 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

English Emma¹²^ORCID,Cook Laura E.²,Piec Isabelle¹^ORCID,Dervisevic Samir¹³,Fraser William D.¹²,John W. Garry¹²

Affiliation:

1. Faculty of Medicine and Health, University of East Anglia, Norfolk, United Kingdom

2. Department of Clinical Biochemistry and Immunology, Norfolk and Norwich University Hospital, Norfolk, United Kingdom

3. Department of Virology, Norfolk and Norwich University Hospital, Norfolk, United Kingdom

Abstract

In the initial stages of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 pandemic, a plethora of new serology tests were developed and introduced to the global market. Many were not evaluated rigorously, and there is a significant lack of concordance in results across methods.

Funder

Abbott | Abbott Diagnostics

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00288-21

Reference24 articles.

1. Worldometer. 2021. COVID-19 coronavirus pandemic. Dover DE USA. https://www.worldometers.info/coronavirus/. Accessed 10 January 2021.

2. World Health Organization. 2021. Weekly epidemiological update on COVID-19 – 16 March 2021. World Health Organization, Geneva, Switzerland.

3. SARS-CoV-2 vaccines in development